Malawi saw nearly five million confirmed cases in 2017 and it has been chosen, along with Kenya and Ghana, to be used in the large-scale pilot of the RTS,S vaccine.
Years of testing supported by a host of organisations, including the Path Malaria Vaccine Initiative, and costing an estimated $1bn (£770m) have led to this point.
The nearly 40% efficacy is not high in comparison with vaccines for other diseases, but the WHO says RTS,S will add to the preventative measures, such as bed nets and insecticides, already being used, AFP news agency reports.
"A vaccine that is highly efficacious, 90% or so, that's not in view at this point," the WHO's Mary Hamel is quoted by Bloomberg as saying.
0 Comments